GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Items 101–200 of 592
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
Ravassa, S., Zudaire, A., Carr, R. D., & Díez, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00885.2010 · Cited by 94
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91
“Previous studies have shown that GLP-1 protects cardiomyocytes and endothelial cells against cell apoptosis by activating ERK1/2 and/or PI3K/Akt [31,44,74].”
BackgroundInfluentialGLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells
Li, Q., Lin, Y., Wang, S., Zhang, L., & Guo, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-06712-z · Cited by 94
Chen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 89
Hocher, B., Sharkovska, Y., Mark, M., Klein, T., & Pfab, T. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.007 · Cited by 92
“Several studies have shown that GLP-1 or GLP-1 analogs limit myocardial infarct size in various animal models [17–19].”
BackgroundNeves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., & Ferreira, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 89
Hoefer, J., Azam, M. A., Kroetsch, J. T., Leong-Poi, H. M., Momen, M. A., Voigtlaender‐Bolz, J., Scherer, E. Q., Meißner, A., Bolz, S., & Husain, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.226464 · Cited by 86
Self-citationYamaoka‐Tojo, M., Tojo, T., Takahira, N., Matsunaga, A., Aoyama, N., Masuda, T., & Izumi, T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-17 · Cited by 87
“However, several experimental studies indicate that they occur independently of effects on glucose metabolism and may involve activation of cyclic guanosine monophosphate/cyclic adenosine monophosphate-dependent pathways and prosurvival kinases such as PI3K, Akt, glycogen synthase kinase-3β, p70s6 kinase, ERK1/2, and…”
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E., Sebastião, I. C., Cardoso, S. M., Correia, S. C., Carvalho, C. I., Plácido, A. I., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 97
Schisano, B., Harte, A. L., Lois, K. B., Saravanan, P., Al‐Daghri, N. M., Al-Attas, O. S., Knudsen, L. B., McTernan, P. G., Ceriello, A., & Tripathi, G. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.11.008 · Cited by 89
“It can be argued that this result depends on a higher antioxidant activity induced by Liraglutide, as some groups previously reported [27].”
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 88
“This effect was reversed by either DL-12330A, a cAMP inhibitor or PKI(14-22), a PKApecific inhibitor.”
InfluentialZhang, L., Pang, X.-F., Bai, F., Wang, N.-P., Shah, A., McKallip, R. J., Li, X., Wang, X., & Zhao, Z. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6592-7 · Cited by 84
Nuamnaichati, N., Mangmool, S., Chattipakorn, N., & Parichatikanond, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00805 · Cited by 90
“org 13 manner in mouse cardiomyocytes (Noyan-Ashraf et al., 2009).”
Nediani, C., Raimondi, L., Borchi, E., & Cerbai, E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3198 · Cited by 88
“In addition, GLP-1 has shown protective effects on normoglycemic rat hearts and in diabetic cardiac myocytes subjected to ischemia and reperfusion (281, 351).”
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
“Surgical myocardial infarction Experimental myocardial infarction (MI) was induced via permanent ligation of the left anterior descending (LAD) coronary artery in 10e12week-old male mice as described previously [13].”
BackgroundMethodResultInfluentialSelf-citationThe Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 85
“Although liraglutide administration for several days reduced infarct size and rates of death in normal or diabetic mice (57), the cardioprotective mechanism(s) remain elusive.”
BackgroundSelf-citationConcurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
Dietrich, N., Kolibabka, M., Busch, S., Bugert, P., Kaiser, U., Lin, J., Fleming, T. H., Morcos, M., Klein, T., Schlotterer, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167853 · Cited by 84
Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154044 · Cited by 79
Hu, S.-Y., Zhang, Y., Zhu, P., Zhou, H., & Chen, Y.-D. (2017) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2017.01.008 · Cited by 87
Siraj, M. A., Mundil, D., Beca, S., Momen, A., Shikatani, E. A., Afroze, T., Sun, X., Liu, Y., Ghaffari, S., Lee, W. L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci99934 · Cited by 83
“Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP1(9-36) amide against ischemia-reperfusion injury in rat heart.”
BackgroundInfluentialSelf-citationCardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Ulrich, W., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 85
“Using liraglutide, Noyan-Ashraf and coworkers demonstrated cardioprotection after myocardial infarction in diabetic and non-diabetic mice [13].”
BackgroundGLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 78
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Joo, K. W., Kim, S., Ahn, S. Y., Chin, H. J., Chae, D., Lee, J., Han, J. S., & Na, K. Y. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-98 · Cited by 82
“An anti-apoptotic effect mediated by GLP-1R has been suggested in various tissues, including pancreatic beta cells [32], neurons [33], and cardiomyocytes [12].”
BackgroundMethodResultEpac is Required for GLP-1R-Mediated Inhibition of Oxidative Stress and Apoptosis in Cardiomyocytes
Mangmool, S., Hemplueksa, P., Parichatikanond, W., & Chattipakorn, N. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1346 · Cited by 76
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 78
Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 79
“In vitro treatment of cardiomyocyte with GLP-1R agonist reduced caspase-3 cleavage and apoptosis induced by various stimulations such as TNF , hypoxia, and lipidemia [94] [95] [96] .”
BackgroundExenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 75
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
“211 Furthermore, GLP1-1RAs possess vasodilatory properties that contribute to reduced systemic vascular resistance, with relevant benefits for patients with obesity.”
GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway
Ying, Y., Zhu, H., Liang, Z., Ma, X., & Li, S. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0155 · Cited by 75
“…cardioprotective actions in a few http://jme.endocrinology-journals.org DOI: 10.1530/JME-15-0155 2015 The authors Printed in Great Britain ischemia/reperfusion models, leading to improved cardiac function and enhanced cell survival (Ban et al. 2008, Noyan-Ashraf et al. 2009, Timmers et al. 2009).”
BackgroundInfluentialSharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Kristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Mæng, M. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-31 · Cited by 71
“Furthermore a recent study in mice reports benefical effects by Liraglutide administration for 7 days before myocardial ischemia [10].”
Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 72
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S. M., Calderwood, D., Church, R. H., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 75
“Nonetheless, other studies have consistently shown GLP-1 to protect cardiomyocytes from apoptosis both in vivo and in vitro [15, 30], although reported effects on cardiomyocyte hypertrophy have been varied.”
BackgroundMethodResultInfluentialDeciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 67
“(40) examined the cardioprotective mechanisms of action of liraglutide in normoglycemic and diabetic mice with ligation of the left anterior descending coronary artery.”
BackgroundSelf-citationZhang, Y., Wang, S., Chen, X., Wang, Z., Wang, X., Zhou, Q., Fang, W., & Zheng, C. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111560 · Cited by 70
“various biological functions and activates cytoprotective pathways to improve 69 outcomes (7).”
BackgroundAMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You
Butler, P. C., Dry, S., & Elashoff, R. M. (2010) · Diabetes Care · doi:10.2337/dc09-1902 · Cited by 77
“These benefits include cardiovascular protection against ischemia and prevention and/or reversal of the defect in -cell mass that is characteristic of type 2 diabetes (7,8).”
BackgroundCHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 72
Cosentino, F., Verma, S., Ambery, P., Treppendahl, M. B., van Eickels, M., Anker, S. D., Cecchini, M., Fioretto, P., Groop, P., Hess, D. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad445 · Cited by 71
Davies, M. J., Kela, R., & Khunti, K. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 68
“In a mouse model of myocardial infarction (MI), liraglutide treatment significantly improved survival after experimental MI [43].”
BackgroundDipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury
Matheeussen, V., Jungraithmayr, W., & Meester, I. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.012 · Cited by 69
Chinda, K., Sanit, J., Chattipakorn, S. C., & Chattipakorn, N. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113516134 · Cited by 66
Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-011-0359-9 · Cited by 65
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
Chrysant, S. G., & Chrysant, G. S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.398 · Cited by 71
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Self-citationTerasaki, M., Nagashima, M., Watanabe, T., Nohtomi, K., Mori, Y., Miyazaki, A., & Hirano, T. (2012) · Metabolism · doi:10.1016/j.metabol.2011.11.011 · Cited by 64
Chen, J., Wang, D., Wang, F., Shi, S., Chen, Y., Yang, B., Tang, Y., & Huang, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.008 · Cited by 65
Liraglutide: A Review of its Use in Type 2 Diabetes Mellitus
Croom, K. F., & McCormack, P. L. (2009) · Drugs · doi:10.2165/11201060-000000000-00000 · Cited by 65
Mannucci, E., Dicembrini, I., Nreu, B., & Monami, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13888 · Cited by 63
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
“, infarct size reduction and ejection fraction improvement) in experimental models of myocardial ischemia-reperfusion injury by suppressing caspase-3 activation and preventing apoptosis of cardiomyocytes [50,51].”
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
Zhou, Y., He, X., Chen, Y., Huang, Y., Wu, L., & He, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.179 · Cited by 61
Self-citationKu, H.-C., Chen, W., & Su, M. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0665-3 · Cited by 65
“2004a), myocardial infarction (Noyan-Ashraf et al. 2009), and endotoxemia (Ku et al.”
BackgroundIrwin, N., & Flatt, P. R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 64
Aravindhan, K., Bao, W., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130894 · Cited by 59
“In addition, we and others have demonstrated that long acting GLP-1 agonists provide infarct-limiting effects following myocardial ischemia/reperfusion injury in vivo [9,10,11,12].”
BackgroundInfluentialGlucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 65
Soraya, H., Clanachan, A. S., Rameshrad, M., Maleki‐Dizaji, N., Ghazi‐Khansari, M., & Garjani, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.05.003 · Cited by 62
“In contrast, other studies have detected no improvement in outcomes with chronic metformin exposures following experimental myocardial infarction (Noyan-Ashraf et al., 2009).”
ResultYang, M., Ma, X., Xuan, X., Deng, H., Chen, Q., & Yuan, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00432 · Cited by 59
The role of the Wnt signaling pathway in incretin hormone production and function
Chiang, Y., Ip, W., & Jin, T. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00273 · Cited by 63
“GLP-19−36 amide was previously assumed to be inactive, but was subsequently shown to have protective effects in the heart (Nikolaidis et al., 2004; Zhao et al., 2006; Ban et al., 2009; Noyan-Ashraf et al., 2009; Ban et al., 2010; Cho and Kieffer, 2011).”
BackgroundInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“[135] Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi”
BackgroundResultKoshal, P., & Kumar, P. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2678-1 · Cited by 58
Cardiac cAMP-PKA Signaling Compartmentalization in Myocardial Infarction
Colombe, A., & Pidoux, G. (2021) · Cells · doi:10.3390/cells10040922 · Cited by 62
“GLP1R Glucagon Like Peptide 1 Receptor • Coupled to Gαs • Inotropic [13] • Reduces infarct size [50,51]”
BackgroundMurase, H., Kuno, A., Miki, T., Tanno, M., Yano, T., Kouzu, H., Ishikawa, S., Tobisawa, T., Ogasawara, M., Nishizawa, K., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0264-6 · Cited by 59
“Conversely, inhibition of DPP-4 and use of a GLP-1 analog prevented cardiomyopathy, improved cardiac function and post-MI survival rate, and attenuated ventricular remodeling in DM and non-DM animals [27, 29–32].”
Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., & Zhang, J. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.133 · Cited by 57
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 61
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Paul, S. K., Klein, K., Maggs, D. G., & Best, J. H. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0178-3 · Cited by 56
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 59
“These findings were independent of weight loss and were associated with increased expression of proteins involved in cardioprotective signalling pathways in the myocytes [42].”
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
Zhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
“GLP-1R agonist liraglutide improves outcomes after experimental myocardial infarction via Nrf2/ARE pathway (34).”
BackgroundCardioprotective Signature of Short-Term Caloric Restriction
Noyan, H., El-Mounayri, O., Isserlin, R., Arab, S., Momen, A., Cheng, H. S., Wu, J., Afroze, T., Li, R., Fish, J. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130658 · Cited by 56
“Separate groups of AL and CR mice (N = 30/group) underwent permanent left anterior descending (LAD) artery ligation as described previously [25].”
BackgroundMethodResultInfluentialSelf-citationIncretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“It was initially demonstrated that GLP-1R activation enhances cyclic adenosine monophosphate (cAMP) production and prevents apoptosis of cardiomyocytes [19].”
BackgroundHussein, A. M., Eid, E. A., Taha, M., Elshazli, R. M., Bedir, R. F., & Lashin, L. S. (2020) · Biomedicines · doi:10.3390/biomedicines8030043 · Cited by 57
“Also, the GLP1 analogue demonstrated cardioprotective effects against myocardial infarction in mice [28] and cardiac remodeling in type 2 diabetic rats [29].”
BackgroundFerroptosis: mechanism and role in diabetes-related cardiovascular diseases
Wang, Z., Wu, C., Yin, D., & Dou, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02614-x · Cited by 58
Davies, M. J., & Speight, J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01595.x · Cited by 55
Faber, R., Zander, M., Pena, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51
“Other potential beneficial effects of GLP-1 shown in animal studies include increased vasodilatation and coronary flow and activation of cardio protective pathways in murine heart models [13,14].”
BackgroundWong, J. C., & Fiscus, R. R. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22981 · Cited by 52
“The present study using OP9 BMSCs shows that these cells produce detectable levels of ANP precursor [Noyan-Ashraf et al., 2009] (Fig.”
ResultGaspari, T. A., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 55
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 54
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 52
Zhan, J., Wang, Y., Wang, Y., Tang, Z.-Y., Tan, P., Huang, W., & Liu, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.086 · Cited by 51
“Cardioprotective effects of GLP-1 and its analogues have been described recently in several ischemia/reperfusion models [13,27,28].”
BackgroundModulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
Ang, R., Mastitskaya, S., Hosford, P. S., Basalay, M., Specterman, M., Aziz, Q., Li, Y., Orini, M., Taggart, P., Lambiase, P. D., et al. (2018) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.118.006740 · Cited by 47
Rizvi, A. A., Stoian, A. P., Janež, A., & Rizzo, M. (2021) · Biomedicines · doi:10.3390/biomedicines9111579 · Cited by 55
“These findings were confirmed in a real-world setting when the vascular benefit of liraglutide in patients with T2DM was associated with reductions in sdLDL, independent of glycemic control and body weight reduction [49].”
BackgroundResultUssher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 53
“For example, the DPP-4–cleaved GLP-1 peptide GLP-1(9-36), which was originally thought to be inactive, may have direct vascular effects that improve cardiac function (22, 71).”
BackgroundInfluentialHou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 53
Kamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
“Mice administered liraglutide survived longer through effects that were independent of weight loss, perhaps through metabolism or extracardiac GLP-1 receptor pathways.(68) Liraglutide has also been observed to produce a modest but significant reduction in systolic blood pressure compared with placebo and comparator 905”
BackgroundKu, H.-C., Chen, W., & Su, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054518 · Cited by 54
“In addition, the presence of GLP-1 signaling has been demonstrated in cardiac function preservation in various animal model experiments, such as dilated cardiomyopathy, heart failure, and myocardial infarction [1,7,8,9,10,11,12,13].”
BackgroundXiao, Y.-F., Nikolskaya, A., Jaye, D. A., & Sigg, D. C. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-6 · Cited by 47
“These results are along with the findings in the previous studies in rodent cardiomyocytes that GLP-1 or the GLP-1R agonist liraglutide significantly increased intracellular cAMP, which was abolished by the GLP-1R antagonist Exendin (9-39)[13,30].”
BackgroundResultChen, W. R., Tian, F., Chen, Y. D., Wang, J., Yang, J. J., Wang, Z. F., Wang, J. D., & Ning, Q. X. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.009 · Cited by 49
Mima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 49
Li, J., Zheng, J., Wang, S., Lau, H. K., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 47
“…GIP, gastric inhibitory polypeptide; SDF-1, stromal cell-derived factor-1; AMPK, AMPactivated protein kinase; VSMCs, vascular smooth muscle cells; ox-LDL, oxidized low-density lipoprotein; LOX-1, lectin-like oxidized low-density lipoprotein scavenger receptor-1; FMD, flow-mediated vasodilation.”
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.